|
|
Operating income of 13.759 billion yuan! One chart helps you understand the full - year performanceIssuing time:2025-03-26 15:24 
The United Laboratories 2024 Annual Performance Press Conference On March 25th,The United Laboratories held its 2024 Annual Performance Press Conference in Hong Kong. At the conference, it was announced that Lianbang Pharmaceuticals Grouphad an operating income of RMB 13.759 billion in 2024. Among them,the income from intermediates was RMB 2.659 billion,the income from APIs was RMB 6.373 billion,the income from pharmaceutical preparations was RMB 4.728 billion. Cai Haishan, the Chairman of the Board of Directors of The United Laboratories, Liang Yongkang, the Vice - Chairman, Zheng Shunteng, the Senior General Manager of Zhuhai Sales Company, Zhang Yubin, the General Manager of the Pharmaceutical Preparation Marketing Center, Liu Hongchi, the General Manager of the Animal Health Care Business Unit, and Cao Chunlai, the General Manager of Lianbang Biotechnology Company attended the press conference.
About Lianbang Pharmaceuticals Lianbang Pharmaceuticalswas founded in 1990 and is mainly engaged in the R & D, production and sales of pharmaceuticals. It is one of the leading comprehensive pharmaceutical enterprises in China. It was listed on the Hong Kong Stock Exchange on June 15th, 2007 (Stock Code: 3933.HK). After more than thirty years of development, Lianbang Pharmaceuticals has four major business segments: pharmaceutical preparations, raw materials, biotechnology, and animal health care. It has established production and R & D entities in Hong Kong, Zhuhai, Zhongshan, Jiangmen, Bayannur, Hengqin, Ningbo and other places. Its products cover pharmaceutical intermediates, APIs, pharmaceutical preparations, veterinary drugs, health products, medical devices, etc. Its sales network covers the world, and it currently has more than 16,000 employees. 【Source】Group Investor Relations Department, Group Brand and Culture Department 【Editor】Group Brand and Culture Department 【Proofreading】Group Investor Relations Department, Group Brand and Culture Department |
